NAD+ Nanoparticle Injection Decreased Blood Vessel Damage In Rats

A new study found injection of NAD+ using a novel liposome-like nano-particle carrier reduced overgrowth of smooth muscle cells and improved blood vessel healing in rats with narrowed arteries.

“Recently, our team successfully achieved the first in vivo NAD+-replenishing therapy, built on an innovative nano-design featuring a lipid membrane coating.”

Key Points:

  • Reduced uncontrolled growth of surrounding cells
  • Decreased thickening of arterial lining
  • Enhanced regrowth of blood vessel lining in treated arteries
  • Displayed excellent tissue response with no observed adverse effects

Injected NAD+ In Nanoparticles To Improve Artery Widening Outcomes

This study used a rat model of narrowed arteries to determine effectiveness of nanoparticle NAD+ to improve recovery.

Healthy rats undergoing a common artery-widening procedure were divided into treatment groups:

  • Saline (control)
  • NAD+ encased in liposome-like nanoparticles
  • Free NAD+ solution
  • Empty nanoparticle carrier

Treatments were delivered via a single intravenous injection immediately following the artery-opening procedure.


The NAD+ nanoparticles used closely resemble liposomes in structure and function, with comparable bioavailability. Researchers chose this delivery method partially due to high absorption rates, using 1/10 the typical dosage.

Nanoparticle NAD+ Delivery Helps Protect and Regenerate Blood Vessels

Targeted delivery of NAD+ via liposome-like nanoparticles inhibited overgrowth of surrounding muscle cells, a primary contributor to arteries becoming re-blocked over time.

Treatment simultaneously protected and regenerated cells lining blood vessels.

“The overcomes NAD+’s intrinsic limitations by protecting it from degradation and enabling direct intracellular NAD+ delivery through the endocytic pathway.”

The figure below shows the thickness of the tissue lining the arteries of the rats after widening and NAD+ treatment.

From left to right, this figure illustrates the outcomes in each of the four groups.
    • Saline: The saline control group shows the thickest blood vessel lining indicating tissue thickening and cell overgrowth.
    • Empty NP: This group received nanoparticles without NAD+. The lining appears slightly thinner than the control, suggesting a possible minor effect, but not statistically significant.
    • Free NAD+: This group received free NAD+. The lining shows no noticeable difference compared to the control, indicating no effect from free NAD+.
    • P-NAD+-NP: This group received nanoparticle-encased NAD+. The vessels have the thinnest lining, demonstrating the most effective reduction in tissue thickening and cell overgrowth.

“Our technology enabled outstanding preclinical efficacies at mere 1/10 or less dosage (10 mg/kg) with mere one dose over the course of 2 weeks.”

Nanoparticle NAD+ Facilitates Blood Vessel Healing and Reduces Risk of Repeated Artery Blockages

Animals treated with the nanoparticle NAD+ showed:

  • Significant reduction in muscle cell overgrowth
  • Accelerated healing of blood vessel lining
  • No significant adverse effects, indicating high safety profile

Conclusion

NAD+ encased in liposome-like nanoparticle envelopes, not free NAD+, effectively mitigates the cell overgrowth and thickening of blood vessel lining seen after an artery-widening procedure.

This treatment promoted tissue recovery and improved circulatory outcomes.

“The combined innovation allowed us, for the first time, to probe targeted NAD+ repletion as a new avenue in achieving differential management of the two seemingly opposite objectives: anti-restenosis (inhibiting SMC proliferation) and re-endothelialization (promoting EC regeneration).”

Dr. Rebecca Crews profile picture

Dr. Rebecca Crews

Learn More

Leading the company’s engagement in transformative research. She is committed to scientific integrity in the health and wellness space and data transparency with consumers.

She holds a Ph.D. in Biochemical and Molecular Nutrition from Tufts University and has over ten years of nutrition science research experience, exploring various dimensions of human well-being in academic and government laboratories.